Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Phase I/II study of DNA vaccine for hypertension begins in Australia

April 13, 2018

Novel dopamine beta-hydroxylase inhibitors identified at BIAL-Portela & Ca.

April 13, 2018

New TRPV4 antagonists discovered at GlaxoSmithKline

April 11, 2018

FDA grants orphan drug designation for elamipretide for treatment of Barth syndrome

April 10, 2018

Bayer presents novel muscarinic M2 receptor positive allosteric modulators

April 10, 2018

Symic reports 12-month data from SHIELD trial of SB-030 in peripheral vascular disease

April 3, 2018

Sakigake designation awarded to tafamidis meglumine

March 29, 2018

Japanese authorities grant Sakigake designation to CLBS-12

March 29, 2018

Servier initiates phase I study of MRG-110

March 28, 2018

First patient enrolled in phase III AEGIS-II study of CSL-112

March 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...